Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 4
2020 9
2021 6
2022 12
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yongjun pan (10 results)?
MNK2 governs the macrophage antiinflammatory phenotype.
Bartish M, Tong D, Pan Y, Wallerius M, Liu H, Ristau J, de Souza Ferreira S, Wallmann T, van Hoef V, Masvidal L, Kerzel T, Joly AL, Goncalves C, Preston SEJ, Ebrahimian T, Seitz C, Bergh J, Pietras K, Lehoux S, Naldini L, Andersson J, Squadrito ML, Del Rincón SV, Larsson O, Rolny C. Bartish M, et al. Among authors: pan y. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27556-27565. doi: 10.1073/pnas.1920377117. Epub 2020 Oct 19. Proc Natl Acad Sci U S A. 2020. PMID: 33077599 Free PMC article.
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study.
Pan Y, Zhu X, Liu J, Zhong J, Zhang W, Shen S, Jin R, Liu H, Ye F, Hu K, Xu D, Zhang Y, Chen Z, Xing B, Zhou L, Chen Y, Zeng Y, Liang X, Kuang M, Song T, Xiang B, Wang K, Sun H, Xu L; China Liver Cancer Study Group Young Investigators (CLEAP). Pan Y, et al. Front Immunol. 2023 Apr 26;14:1138355. doi: 10.3389/fimmu.2023.1138355. eCollection 2023. Front Immunol. 2023. PMID: 37180173 Free PMC article.
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.
Liu J, Zhu X, Pan Y, Zhong J, Jin R, Zheng X, Zhang W, Hu K, Ma J, Shi X, Liu H, Yang X, Xu D, Ma C, Chen J, Wang D, Wang X, Li Z, Zhao L, Zhang L, Li T, Liu F, Tan G, Xing B, Zhao H, Zeng Y, Zhang S, Zhang L, Zhou L, Song T, Yang W, Liang X, Xiang B, Xu L, Sun H, Wang K. Liu J, et al. Among authors: pan y. Oncologist. 2024 Apr 4;29(4):e487-e497. doi: 10.1093/oncolo/oyad277. Oncologist. 2024. PMID: 37874924 Free PMC article.
Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
Pan Y, Wang R, Hu D, Xie W, Fu Y, Hou J, Xu L, Zhang Y, Chen M, Zhou Z. Pan Y, et al. Front Biosci (Landmark Ed). 2021 Oct 30;26(10):873-881. doi: 10.52586/4994. Front Biosci (Landmark Ed). 2021. PMID: 34719212 Free article. Review.
45 results